GLP-1 Weight Loss: Your Questions, Answered Honestly

MEDICAL SOURCES & FURTHER READING

Check the source and its limits. The notes below explain which medical information each reference supports; they are not patient-specific advice or evidence of this clinic's results.

1. Wegovy (semaglutide) injection — prescribing information

   Sections 1–6 and the Medication Guide cover eligibility, dose escalation, GLP-1 action, gastrointestinal effects, thyroid-tumor warnings, pancreatitis, gallbladder disease, volume depletion and pregnancy precautions.

   Evidence limits: This dated label is for FDA-approved Wegovy injection. Follow the current label for your specific product and your prescriber's instructions; it does not establish the safety or effectiveness of a compounded preparation.

2. Zepbound (tirzepatide) injection — prescribing information

   Sections 1–6 and 12 describe GIP/GLP-1 receptor activity, eligibility, gradual dose escalation, common adverse reactions, contraindications and important safety warnings. Section 8 addresses pregnancy and oral contraceptive precautions.

   Evidence limits: Applies to the approved Zepbound product, not every tirzepatide preparation. Trial adverse-event frequencies are product- and population-specific.

3. Prescription Medications to Treat Overweight & Obesity

   Explains provider assessment, BMI and health considerations, medication mechanisms, use alongside nutrition and activity, treatment duration and possible weight regain after stopping.

   Evidence limits: General education, not a determination of any patient's eligibility or an endorsement of this clinic.

4. Nutritional priorities to support GLP-1 therapy for obesity: A joint Advisory from the American College of Lifestyle Medicine, the American Society for Nutrition, the Obesity Medicine Association, and The Obesity Society

   This published clinical advisory discusses adequate nutrition and hydration, individualized protein intake, gastrointestinal symptom management, resistance exercise, muscle function and nutrient-deficiency screening during GLP-1 treatment.

   Evidence limits: A literature-informed advisory, not a trial proving a particular meal plan, universal protein/fluid target, or guaranteed muscle preservation. The source includes a linked 2026 correction.

5. Body composition changes during weight reduction with tirzepatide in the SURMOUNT-1 study of adults with obesity or overweight

   Research published in Diabetes, Obesity and Metabolism reported loss of both fat and lean mass in a 160-participant DXA substudy. Approximately three-quarters of weight lost was fat and one-quarter lean mass in both tirzepatide and placebo groups.

   Evidence limits: Lean mass is not the same as skeletal muscle or muscle function. This sponsor-funded substudy does not establish superiority in muscle preservation or prove that muscle loss can be eliminated. The source record includes a linked correction.

6. Understanding the Risks of Compounded Drugs

   Compounded drugs are not FDA-approved and are not reviewed by FDA for safety, effectiveness or quality before marketing. Compounding may address a patient-specific medical need but carries quality and dosing risks.

Compounded drugs are not FDA-approved. The FDA does not review compounded drugs for safety, effectiveness or quality before marketing. Compounded preparations are not established as equivalent to FDA-approved products. Patient-specific need and applicable compounding requirements must be evaluated by the prescriber and pharmacy.

These independent information sources do not endorse, sponsor or affiliate with South Florida Trim Clinic. Education is not a substitute for individualized medical advice. Prescription treatment requires evaluation by an appropriately licensed healthcare provider.